109 related articles for article (PubMed ID: 19412811)
1. No direct effects of erythropoietin beta on a head and neck squamous cell carcinoma cell line which is growth stimulated in vivo.
Sasaki Y; Kjellén E; Mineta H; Wennerberg J; Ekblad L
Acta Oncol; 2009; 48(7):1062-9. PubMed ID: 19412811
[TBL] [Abstract][Full Text] [Related]
2. Recombinant erythropoietin beta enhances growth of xenografted human squamous cell carcinoma of the head and neck after surgical trauma.
Kjellén E; Sasaki Y; Kjellström J; Zackrisson B; Wennerberg J
Acta Otolaryngol; 2006 May; 126(5):545-7. PubMed ID: 16698707
[TBL] [Abstract][Full Text] [Related]
3. Erythropoietin-mediated activation of JAK-STAT signaling contributes to cellular invasion in head and neck squamous cell carcinoma.
Lai SY; Childs EE; Xi S; Coppelli FM; Gooding WE; Wells A; Ferris RL; Grandis JR
Oncogene; 2005 Jun; 24(27):4442-9. PubMed ID: 15856028
[TBL] [Abstract][Full Text] [Related]
4. Recombinant erythropoietin differently affects proliferation of mesothelioma cells but not sensitivity to cisplatin and pemetrexed.
Palumbo C; Battisti S; Carbone D; Albonici L; Alimandi M; Bei R; Modesti A
Cancer Chemother Pharmacol; 2008 Apr; 61(5):893-901. PubMed ID: 17922127
[TBL] [Abstract][Full Text] [Related]
5. Recombinant human erythropoietin alpha improves the efficacy of radiotherapy of a human tumor xenograft, affecting tumor cells and microvessels.
Lövey J; Bereczky B; Gilly R; Kenessey I; Rásó E; Simon E; Dobos J; Vágó A; Kásler M; Döme B; Tímár J; Tóvári J
Strahlenther Onkol; 2008 Jan; 184(1):1-7. PubMed ID: 18188516
[TBL] [Abstract][Full Text] [Related]
6. Erythropoietin receptor is not a surrogate marker for tumor hypoxia and does not correlate with survival in head and neck squamous cell carcinomas.
Hoogsteen IJ; Peeters WJ; Marres HA; Rijken PF; van den Hoogen FJ; van der Kogel AJ; Kaanders JH
Radiother Oncol; 2005 Aug; 76(2):213-8. PubMed ID: 16112214
[TBL] [Abstract][Full Text] [Related]
7. Recombinant human erythropoietin alpha targets intratumoral blood vessels, improving chemotherapy in human xenograft models.
Tóvári J; Gilly R; Rásó E; Paku S; Bereczky B; Varga N; Vágó A; Tímár J
Cancer Res; 2005 Aug; 65(16):7186-93. PubMed ID: 16103069
[TBL] [Abstract][Full Text] [Related]
8. STI-571 (Gleevec) potentiates the effect of cisplatin in inhibiting the proliferation of head and neck squamous cell carcinoma in vitro.
Wang-Rodriguez J; Lopez JP; Altuna X; Chu TS; Weisman RA; Ongkeko WM
Laryngoscope; 2006 Aug; 116(8):1409-16. PubMed ID: 16885745
[TBL] [Abstract][Full Text] [Related]
9. Erythropoietin stimulates growth and STAT5 phosphorylation in human prostate epithelial and prostate cancer cells.
Feldman L; Wang Y; Rhim JS; Bhattacharya N; Loda M; Sytkowski AJ
Prostate; 2006 Feb; 66(2):135-45. PubMed ID: 16161153
[TBL] [Abstract][Full Text] [Related]
10. Lack of expression and function of erythropoietin receptors in the kidney.
Elliott S; Busse L; Swift S; McCaffery I; Rossi J; Kassner P; Begley CG
Nephrol Dial Transplant; 2012 Jul; 27(7):2733-45. PubMed ID: 22167585
[TBL] [Abstract][Full Text] [Related]
11. Regulation of the steps of angiogenesis by human head and neck squamous cell carcinomas.
Benefield J; Petruzzelli GJ; Fowler S; Taitz A; Kalkanis J; Young MR
Invasion Metastasis; 1996; 16(6):291-301. PubMed ID: 9371228
[TBL] [Abstract][Full Text] [Related]
12. [The effect of the microenvironment of head and neck cancers on tumor progression].
Lukits J
Magy Onkol; 2009 Mar; 53(1):51-9. PubMed ID: 19318327
[TBL] [Abstract][Full Text] [Related]
13. Do erythropoietin receptors on cancer cells explain unexpected clinical findings?
Henke M; Mattern D; Pepe M; Bézay C; Weissenberger C; Werner M; Pajonk F
J Clin Oncol; 2006 Oct; 24(29):4708-13. PubMed ID: 17028293
[TBL] [Abstract][Full Text] [Related]
14. Targeted near-infrared imaging of the erythropoietin receptor in human lung cancer xenografts.
Doleschel D; Mundigl O; Wessner A; Gremse F; Bachmann J; Rodriguez A; Klingmüller U; Jarsch M; Kiessling F; Lederle W
J Nucl Med; 2012 Feb; 53(2):304-11. PubMed ID: 22228796
[TBL] [Abstract][Full Text] [Related]
15. EGFR antisense treatment of human HNSCC cell lines down-regulates VEGF expression and endothelial cell migration.
Riedel F; Götte K; Li M; Hörmann K; Grandis JR
Int J Oncol; 2002 Jul; 21(1):11-6. PubMed ID: 12063543
[TBL] [Abstract][Full Text] [Related]
16. Insulin-like growth factor binding protein-5 (IGFBP-5) suppresses the tumourigenesis of head and neck squamous cell carcinoma.
Hung PS; Kao SY; Shih YH; Chiou SH; Liu CJ; Chang KW; Lin SC
J Pathol; 2008 Feb; 214(3):368-76. PubMed ID: 18085517
[TBL] [Abstract][Full Text] [Related]
17. Role of nitric oxide in the development of distant metastasis from squamous cell carcinoma.
Scher RL
Laryngoscope; 2007 Feb; 117(2):199-209. PubMed ID: 17277613
[TBL] [Abstract][Full Text] [Related]
18. Erythropoiesis-stimulating agent use in cancer: preclinical and clinical perspectives.
Arcasoy MO
Clin Cancer Res; 2008 Aug; 14(15):4685-90. PubMed ID: 18676735
[TBL] [Abstract][Full Text] [Related]
19. Abrogation of VEGF expression in human head and neck squamous cell carcinoma decreases angiogenic activity in vitro and in vivo.
Riedel F; Götte K; Li M; Hörmann K; Grandis JR
Int J Oncol; 2003 Sep; 23(3):577-83. PubMed ID: 12888890
[TBL] [Abstract][Full Text] [Related]
20. Recombinant human erythropoietin in combination with chemotherapy increases breast cancer metastasis in preclinical mouse models.
Hedley BD; Chu JE; Ormond DG; Beausoleil MS; Boasie A; Allan AL; Xenocostas A
Clin Cancer Res; 2011 Oct; 17(19):6151-62. PubMed ID: 21856770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
